Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularMedicationIssue 648

Sulfonylurea's Cardiotoxicity Probed

The risk of ischemic events may be higher with a specific subclass of sulfonylureas.... 
Advertisement

Dr. Scot Simpson (University of Alberta, Edmonton), at the European Association for the Study of Diabetes 2012 Annual Meeting, reported that rates of ACS-related hospitalization or death were higher among patients taking glyburide than those taking gliclazide.

Simpson and colleagues reviewed administrative health records for the province of Alberta, Canada, identifying more than 11,000 diabetic patients using either gliclazide or glyburide who also had a history of ischemic heart disease. Over 1000 person-years, researchers saw 99.6 ACS-related hospitalizations or deaths among patients taking glyburide and 88.9 among patients taking gliclazide as their only sulfonylurea. The difference was small but statistically different (p<0.05), Simpson stressed. ACS-related hospitalizations were also slightly higher among glyburide users (87.7 vs 78.1; p<0.05). ACS-related deaths were not statistically different.

Expressed as an incident-rate ratio, the risk of an ACS-related hospitalization or death was increased 14% and the risk of an ACS-related hospitalization was increased by 16%. This yielded a number needed to harm of 25 for the combined primary end point and 34 for ACS hospitalizations.

"It's an ongoing debate: are sulfonylureas safe?" Simpson stated that, "Our take on this is, if you look at sulfonylureas vs no sulfonylureas, they probably are worse than other diabetes drugs, like metformin or the GLP-1s, although we don't have much data yet on these for long-term safety and efficacy. We wanted to ask, if you have to start a sulfonylurea, which is the safer or better one? And what we are showing in this study is that probably using gliclazide is a bit safer than glyburide, but the magnitude of the difference is very, very small."

The clinical impact of this difference, Simpson conceded, is "debatable." He believes the data may have more value from a public-policy standpoint -- for example, which drug should be listed on government formularies -- but he acknowledged that this study, on its own, won't carry a lot of weight.

He and his colleagues are working on the theory that the different results for the two sulfonylureas may relate to their different effects on ischemic preconditioning, since, at usual therapeutic doses, glyburide is more likely to inhibit cardiac KATP channels, potentially blunting the heart's ability to protect against ischemia.

Since a randomized controlled trial comparing the two agents is unlikely, another way to explore this theory would be to look at infarct size, Simpson suggested, or compare other clinical outcomes.

Dr. Nick Wareham (Institute of Metabolic Science, Cambridge, UK), Session moderator, however, expressed caution over the study results, stating that, "These are preliminary data, they're observational, there are all sorts of potential confounding factors, and I think it's a bit premature to leap to any conclusions."

In particular, he said that speculation about a differential effect on ischemic preconditioning is a stretch. For example, choice of one sulfonylurea over another might just be a marker for different types of physician prescribing habits, Wareham noted.

Abdelmoneim A, Eurich DT, Gamble JM, et al. Risk of acute coronary syndrome differs with glyburide and gliclazide treatment in patients with type 2 diabetes and ischaemic heart disease: A population-based cohort study. European Association for the Study of Diabetes 2012 Meeting; October 2, 2012; Berlin, Germany. 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 18 October, 2012 and appeared in  CardiovascularMedicationIssue 648

Past five issues: Diabetes Clinical Mastery Series Issue 208 | Issue 748 | GLP-1 Special Editions September 2014 | Diabetes Clinical Mastery Series Issue 207 | Issue 747 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
FDA Approves Bupropion/Naltrexone (Contrave) for Obesity by Orexigen Therapeutics
Posted September 12, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
An Exclusive Interview with Al Mann, Founder and CEO, Mannkind Corp.
Posted September 15, 2014
FDA Approves Once-Weekly GLP-1 Diabetes Treatment Regimen for T2DM
Posted September 25, 2014
Sleeve Gastrectomy Now a Common Choice for Bariatric Surgery
Posted September 12, 2014
Type 2 Diabetes Diagnosis Needs to Be Changed: Prediabetes=Diabetes
Posted September 12, 2014
High-salt Diet and High HBA1c May Increase Cardiovascular Disease
Posted September 19, 2014
Predicting Which Diabetics Will Develop Major Complications
Posted September 05, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
Deepak Bhatt, MD, MPH, and Jeffrey J. Popma, MD

Category: Cardiology
Credits:
 1
Search Articles On Diabetes In Control